EP 244: Building the first n-of-1 ASO with Timothy Yu of Boston Children’s Hospital

Value of the Information & Strength of the Argument

The value of the information is high, as it provides unique insights from a pioneer in n-of-1 ASO therapy, including practical challenges and strategies. The argumentation is solid, based on real cases and ongoing research, though it is largely anecdotal and lacks quantitative data. The discussion is well-structured and addresses key aspects of the field, but the lack of peer-reviewed references limits its scientific rigor.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is moderate; the content is based on expert opinion and personal experience rather than systematic review. The sources are not explicitly cited in the video, but the description mentions collaborations and frameworks. The title accurately reflects the content, and the video is well-organized with clear chapters. No comments were provided for analysis.

The title accurately reflects the content, focusing on the development of n-of-1 ASO therapies with Timothy Yu.

8/10

The content is an expert interview with a leading researcher in the field, providing firsthand insights and practical experience. The discussion is grounded in real cases and ongoing research, but lacks detailed references to peer-reviewed literature and is largely anecdotal.

• 00:00Intro to The Genetics Podcast
• 01:00Welcome to Tim
• 02:09How uncovering the genetic mutation underlying an ultra-rare disease led Tim into personalized ASO medicine
• 08:12Challenges in developing a custom ASO
• 13:29How Tim’s team has scaled individualized ASO therapies to reach more than 50 patients worldwide
• 17:50Measuring clinical benefit in n-of-1 therapies with natural history data, wearables, and biomarkers
• 22:30How the N-of-1 Collaborative helps rare disease researchers share infrastructure
• 27:00Comparing ASOs, base editing, and prime editing for individualized rare disease therapies
• 33:25Finding scalable models for n-of-1 therapies in newborn genetic disease
• 37:30The potential impact of the FDA’s Plausible Mechanism framework on bespoke therapies
• 40:59Connecting rapid newborn genome sequencing to earlier treatment for rare genetic disease
• 46:53Closing remarks

• N-of-1 Collaborative — Mentioned as a nonprofit to share infrastructure and knowledge for n-of-1 therapies.
• FDA Plausible Mechanism framework — Discussed as a potential regulatory pathway for bespoke therapies.

• N-of-1 Collaborative — The video mentions this organization as a key resource for sharing infrastructure.